|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5202238A
(en)
|
1987-10-27 |
1993-04-13 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
|
IL101661A
(en)
|
1991-04-23 |
1998-02-08 |
Regeneron Pharma |
Method for detecting, identifying or measuring agents having neurotrophin activity
|
|
WO1994009817A1
(en)
|
1992-11-04 |
1994-05-11 |
City Of Hope |
Novel antibody construct
|
|
JP3720353B2
(ja)
|
1992-12-04 |
2005-11-24 |
メディカル リサーチ カウンシル |
多価および多重特異性の結合タンパク質、それらの製造および使用
|
|
US6838254B1
(en)
|
1993-04-29 |
2005-01-04 |
Conopco, Inc. |
Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
|
|
DE69529674T3
(de)
|
1994-04-04 |
2007-06-28 |
Regeneron Pharmaceuticals, Inc. |
Biologisch aktive liganden der eph-familie
|
|
WO1996021012A1
(en)
|
1994-12-30 |
1996-07-11 |
Planet Biotechnology, Inc. |
Methods for producing immunoglobulins containing protection proteins in plants and their use
|
|
GB9501079D0
(en)
|
1995-01-19 |
1995-03-08 |
Bioinvent Int Ab |
Activation of T-cells
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
EP0739981A1
(en)
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
|
|
EP0826696B1
(de)
|
1996-09-03 |
2002-05-29 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
|
|
AU7266698A
(en)
|
1997-04-30 |
1998-11-24 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
|
PT1049787E
(pt)
|
1998-01-23 |
2005-04-29 |
Vlaams Interuniv Inst Biotech |
Derivados de anticorpos multipropositos
|
|
US20020142000A1
(en)
|
1999-01-15 |
2002-10-03 |
Digan Mary Ellen |
Anti-CD3 immunotoxins and therapeutic uses therefor
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
US20040116330A1
(en)
|
2001-04-27 |
2004-06-17 |
Kenichiro Naito |
Preventive/therapeutic method for cancer
|
|
CA2457636C
(en)
|
2001-08-10 |
2012-01-03 |
Aberdeen University |
Antigen binding domains
|
|
ES2276735T3
(es)
|
2001-09-14 |
2007-07-01 |
Affimed Therapeutics Ag |
Anticuerpos fv multimericos de cadena sencilla en tandem.
|
|
ES2283368T3
(es)
|
2001-11-14 |
2007-11-01 |
Affimed Therapeutics Ag |
Anticuerpos biespecificos anti-cd19 y anti-cd16 y usos de los mismos.
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
GB0230201D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Retargeting
|
|
CA2517054C
(en)
|
2003-02-25 |
2016-05-10 |
Medinnova As |
Use of nucleic acids encoding antibody-like molecules for use in medical treatment
|
|
US20050033031A1
(en)
|
2003-08-07 |
2005-02-10 |
Couto Fernando Jose Rebelo Do |
Methods for humanizing rabbit monoclonal antibodies
|
|
CA2544074A1
(en)
|
2003-10-24 |
2005-05-06 |
Esbatech Ag |
Method for the identification and/or validation of receptor tyrosine kinase inhibitors
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
MXPA06011538A
(es)
|
2004-04-06 |
2007-01-26 |
Univ California |
Tirosina cinasa de receptor huerfano como un objetivo en cancer de mama.
|
|
DK2330121T3
(en)
|
2004-06-02 |
2014-12-15 |
Adalta Pty Ltd |
Binding moieties based on shark IgNar domains
|
|
US20090298195A1
(en)
|
2005-01-05 |
2009-12-03 |
F-Star Biotechnologische Forschungs-Und Entwicklun Gseges M.B.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
US20060206947A1
(en)
|
2005-02-28 |
2006-09-14 |
Scallon Bernard J |
Heterodimeric protein binding compositions
|
|
CN101198698B
(zh)
|
2005-03-31 |
2014-03-19 |
中外制药株式会社 |
通过调节多肽缔合制备多肽的方法
|
|
ES2707152T3
(es)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
|
JP2009504685A
(ja)
|
2005-08-15 |
2009-02-05 |
アラーナ・テラピューティクス・リミテッド |
新世界霊長類フレームワーク領域を用いる設計された抗体
|
|
JP5686953B2
(ja)
*
|
2005-10-11 |
2015-03-18 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
|
|
EP1948680A4
(en)
|
2005-10-28 |
2010-01-13 |
Univ California |
METHOD AND COMPOUNDS FOR DETECTING AND ISOLATING LYMPHOMA CELLS
|
|
WO2008103849A2
(en)
|
2007-02-21 |
2008-08-28 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
|
WO2007110205A2
(en)
|
2006-03-24 |
2007-10-04 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
JP2009538273A
(ja)
|
2006-04-14 |
2009-11-05 |
トルビオン ファーマシューティカルズ， インコーポレイテッド |
改造されたＦＣエフェクター機能を持つ、免疫グロブリン・ヒンジ領域とＦｃ領域とを備える結合タンパク質
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
WO2007146957A2
(en)
|
2006-06-13 |
2007-12-21 |
Irm Llc |
Ror1 as a therapeutic target for lung cancer
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
WO2008036449A2
(en)
|
2006-06-29 |
2008-03-27 |
The Regents Of The University Of California |
Chemical antibodies for immunotherapy and imaging
|
|
WO2008076868A2
(en)
|
2006-12-18 |
2008-06-26 |
Abbott Laboratories |
Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
|
|
CN104497143B
(zh)
|
2007-03-29 |
2020-08-25 |
健玛保 |
双特异性抗体及其制造方法
|
|
SG10201808730VA
(en)
|
2007-04-03 |
2018-11-29 |
Amgen Res Munich Gmbh |
Cross-species-specific binding domain
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
EP3663318A1
(en)
*
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
EP2265283B1
(en)
|
2008-03-18 |
2014-09-03 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
|
US20100260668A1
(en)
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
US8710022B2
(en)
|
2008-07-18 |
2014-04-29 |
National University Corporation Nagoya University |
Cell proliferation inhibitor
|
|
SG194399A1
(en)
*
|
2008-10-01 |
2013-11-29 |
Amgen Res Munich Gmbh |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
CA2745439C
(en)
|
2008-12-03 |
2019-10-15 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
AU2010238723A1
(en)
|
2009-04-23 |
2011-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human ROR1 antibodies
|
|
AU2010245011B2
(en)
|
2009-04-27 |
2015-09-03 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
TW201109438A
(en)
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
|
WO2011079902A2
(en)
|
2009-12-18 |
2011-07-07 |
Biolnvent International Ab |
Biological materials and uses thereof
|
|
SI2519543T1
(sl)
|
2009-12-29 |
2016-08-31 |
Emergent Product Development Seattle, Llc |
Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
|
|
EP2569337A1
(en)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
|
CN102330723A
(zh)
|
2010-07-13 |
2012-01-25 |
新秩序投资119股份有限公司 |
管配件
|
|
EP3219731A1
(en)
*
|
2010-10-01 |
2017-09-20 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
|
PL2635607T3
(pl)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
TWI638833B
(zh)
|
2010-11-30 |
2018-10-21 |
中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
CA2818992C
(en)
*
|
2010-12-01 |
2021-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric rabbit/human ror1 antibodies
|
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
|
CA2858350A1
(en)
|
2011-01-14 |
2013-07-19 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
|
AR085403A1
(es)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos
|
|
AU2012235758B2
(en)
|
2011-03-25 |
2015-05-07 |
IGI Therapeutics SA |
Hetero-dimeric immunoglobulins
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
WO2012158818A2
(en)
*
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
JP5997151B2
(ja)
|
2011-06-30 |
2016-09-28 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
EP3321286B1
(en)
*
|
2011-08-23 |
2021-01-06 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
|
US20130078250A1
(en)
*
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
|
ES2732712T3
(es)
|
2011-10-31 |
2019-11-25 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
|
|
PT2794905T
(pt)
|
2011-12-20 |
2020-06-30 |
Medimmune Llc |
Polipéptidos modificados para estrutura de anticorpos bispecíficos
|
|
DK2838918T3
(da)
|
2012-04-20 |
2019-08-12 |
Merus Nv |
Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
|
|
HK1203517A1
(en)
*
|
2012-05-24 |
2015-10-30 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
CA2881966C
(en)
|
2012-08-24 |
2020-10-06 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
|
WO2014056783A1
(en)
*
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
UY35148A
(es)
*
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US9963513B2
(en)
|
2013-02-05 |
2018-05-08 |
Engmab Sàrl |
Method for the selection of antibodies against BCMA
|
|
WO2014131712A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
JP6501270B2
(ja)
*
|
2013-03-14 |
2019-04-17 |
ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ |
標的化剤抗体抱合体およびその使用
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
UA117289C2
(uk)
*
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
BR112016027888A2
(pt)
*
|
2014-05-28 |
2017-10-24 |
Zymeworks Inc |
construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado
|
|
EP2982692A1
(en)
*
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
RS65573B1
(sr)
*
|
2014-08-04 |
2024-06-28 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije
|
|
MX2017003247A
(es)
*
|
2014-09-15 |
2017-11-30 |
Amgen Inc |
Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
|
|
CA2963692A1
(en)
*
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
AU2016302881B2
(en)
|
2015-08-03 |
2022-09-15 |
Bristol-Myers Squibb Company |
Monoclonal antibodies against BCMA
|
|
EP3535295A1
(en)
|
2016-11-02 |
2019-09-11 |
EngMab Sàrl |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
|
WO2020219978A1
(en)
|
2019-04-25 |
2020-10-29 |
Celgene Corporation |
Bcma/cd3 bispecific trivalent t-cell engaging (tce) antibodies and their use to treat hematological malignancies
|
|
EP4054725A4
(en)
|
2019-11-05 |
2024-01-10 |
Bristol-Myers Squibb Company |
METHODS OF TREATMENT WITH ANTIBODIES AGAINST BCMA AND CD3
|
|
WO2021092060A1
(en)
|
2019-11-05 |
2021-05-14 |
Engmab Sarl |
Methods of treatment
|
|
IL295471A
(en)
|
2020-02-12 |
2022-10-01 |
Bristol Myers Squibb Co |
Anti-bcma therapy in autoimmune disorders
|
|
EP4142722A1
(en)
|
2020-04-30 |
2023-03-08 |
Bristol-Myers Squibb Company |
Methods of treating cytokine-related adverse events
|